Stock RNAC CARTESIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
21.03 USD +0.62% Intraday chart for Cartesian Therapeutics, Inc. +17.42% +1.68%
Apr. 23 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
Mar. 14 Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement CI

Business Summary

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Number of employees: 38

Members of the board

Members of the board TitleAgeSince

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 17,779,787 6,865,116 ( 38.61 %) 0 38.61 %

Shareholders

NameEquities%Valuation
Michael Singer
14.49 %
23,473,393 14.49 % 15 M $
Fidelity Management & Research Co. LLC
10.42 %
16,869,200 10.42 % 11 M $
Artal Group SA
5.642 %
9,136,635 5.642 % 6 M $
Invus Public Equities Advisors LLC
5.642 %
9,136,635 5.642 % 6 M $
Fidelity Management & Research Co. LLC
4.772 %
7,728,437 4.772 % 5 M $
Vanguard Fiduciary Trust Co.
4.473 %
7,244,032 4.473 % 5 M $
BlackRock Advisors LLC
4.446 %
7,199,499 4.446 % 5 M $
Timothy Springer
3.893 %
6,305,089 3.893 % 4 M $
Murat Kalayoglu
2.188 %
3,543,264 2.188 % 2 M $
Elizabeth Hoge
2.188 %
3,543,264 2.188 % 2 M $

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.03 USD
Average target price
56.25 USD
Spread / Average Target
+167.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CARTESIAN THERAPEUTICS, INC. Stock Cartesian Therapeutics, Inc.
+1.68% 374M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RNAC Stock
  4. Company Cartesian Therapeutics, Inc.